Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
Am J Obstet Gynecol
; 207(1): 36.e1-8, 2012 Jul.
Article
em En
| MEDLINE
| ID: mdl-22727345
ABSTRACT
OBJECTIVE:
We sought to identify biomarkers associated with progestin therapy resistance and persistence/progression of endometrial hyperplasia. STUDYDESIGN:
We performed a nested case-control study among women with complex (n = 73) and atypical (n = 41) hyperplasia treated with oral progestin, followed up 2-6 months for persistence/progression. We evaluated index endometrial protein expression for progesterone receptor isoform A, progesterone receptor isoform B (PRB), PTEN, Pax-2, and Bcl-2. Odds ratios and 95% confidence intervals (CIs) were estimated.RESULTS:
Among women with atypical hyperplasia, high PRB expression was associated with 90% decreased risk of persistence/progression (95% CI, 0.01-0.8). High expression of progesterone receptor A and PRB suggested decreased risk of persistence/progression (odds ratio, 0.1; 95% CI, 0.02-1.0). These findings were not observed among women with complex hyperplasia. No associations were found with PTEN, Pax-2, and Bcl-2 protein expression.CONCLUSION:
PRB expression shows promise as a biomarker of progestin response. Further research is warranted to understand how PRB expression may guide treatment decisions.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Progestinas
/
Receptores de Progesterona
/
Proteínas Proto-Oncogênicas c-bcl-2
/
Hiperplasia Endometrial
/
PTEN Fosfo-Hidrolase
/
Fator de Transcrição PAX2
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article